AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 OCT 1 - (NewsRx.com & NewsRx.net) -- A Frederick, Maryland, pharmaceutical firm has received an $11 million federal grant to develop a vaccine against the botulinum bacteria, which can produce the deadliest naturally occurring toxin known to man and is a potential biological weapon.
Dynport Vaccine Co. LLC said it will work with Army scientists from nearby Fort Detrick as well as researchers from Nebraska, Colorado, and California on a vaccine that will be effective against all seven known types of neurotoxin produced by the Clostridium botulinum bacteria.
The only licensed botulinum defense is an antitoxin effective against just three types of the toxin, and only after infection. A seven-way antitoxin and a five-way vaccine are in the investigational phase.
In addition to being more broadly effective, the vaccine will be made by gene splicing, which requires a lower level of biosafety containment, said Caree Vander Linden, a spokeswoman for the U.S. Army Medical Institute of Infectious Diseases.
"It basically employs a newer technique" for developing "the next-generation vaccine," she said.
Dynport is a joint venture of Computer Sciences Corp., of El Segundo, California, and Porton International, Inc., a subsidiary of the Ipsen Group of France. The grant, announced by Computer Sciences Corp., is from the National Institute of Allergy and ...